HRT8 min read
Fezolinetant’s liver warning: what postmarketing evidence can reveal
How fezolinetant's liver warning changed after approval, what trials could detect, and what the current monitoring plan means.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
HRT articles
All articlesMenopause, hormones and treatment options
HRT9 min read
Elinzanetant after approval: what the OASIS trials actually added
What the OASIS trials established about elinzanetant—and why symptom efficacy, sleep outcomes and current approval need separate interpretation.
Read article
HRT8 min read
The 2026 HRT label changes: what changed, and what still matters
FDA revised warnings for six menopause products. Here is how to understand the changes, retained risks and differences between systemic and local therapy.
Read article
HRT8 min read
Bleeding on HRT: what NICE's 2026 update means for your next step
NICE's updated bleeding timeline helps frame an HRT review. Learn why regimen, bleeding pattern and medical history matter alongside ultrasound or biopsy.
Read article
HRT9 min read
Menopause Brain Fog: Why Dementia-Prevention Claims Go Too Far
Menopause brain fog, cognitive test scores and dementia are different outcomes. Learn what the trials and 2026 label changes actually show.
Read article
HRT9 min read
Testosterone for women: desire, energy and strength are different questions
Testosterone has evidence for a defined sexual-health problem, but claims about energy, cognition and strength require separate answers.
Read article
HRT9 min read
HRT after breast cancer: why local and systemic treatment need separate discussions
Local vaginal estrogen and systemic HRT raise different questions after breast cancer. Understand recurrence findings, mortality data and endocrine treatment.
Read article
HRT9 min read
The hormone-panel trap in perimenopause
A normal hormone result does not rule out perimenopause. Learn why timing matters, when tests help and how targeted assessment differs from hormone panels.
Read article
HRT9 min read
Does everyone need to stop HRT at 65?
Age 65 is not an automatic HRT stopping point. Explore continuation versus late initiation, randomized findings and the limits of large observational studies.
Read article
HRT9 min read
Patches Versus Pills: What Route Can Change About HRT Risk
Why delivery through skin changes the evidence on venous clots, and why dose, progestogen and individual history still matter.
Read article
HRT8 min read
HRT and GLP-1 treatment: separate goals, coordinated care
Separate the benefits, evidence and monitoring needs of HRT and GLP-1 treatment, including oral progestogen and contraception questions.
Read article
HRT9 min read
The Underreported Menopause Story: Recurrent Urinary Symptoms
Recurrent urinary symptoms around menopause need both infection assessment and attention to local tissue changes. Here is what prevention trials show.
Read article1–12 of 30 articles